60 Degrees Pharmaceuticals Inc
SXTP
Company Profile
Business description
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
Contact
1025 Connecticut Avenue NW
Suite 1000
Washington, D.CWA20036
USAT: +1 202 327-5422
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
3
Stocks News & Analysis
stocks
Netflix and Warner Bros. Discovery: Surprisingly high merger price alters shareholder value for both
Our view on the blockbuster merger.
stocks
The trillion-dollar club: Are these mega-sized stocks still buys?
The biggest stocks got bigger this year, breaking multi-trillion-dollar milestones.
stocks
New pricing model for embattled ASX tech leader
Investor day shows off potentially disruptive pricing model.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,926.10 | 19.30 | 0.22% |
| CAC 40 | 8,114.74 | 7.29 | -0.09% |
| DAX 40 | 24,028.14 | 146.11 | 0.61% |
| Dow JONES (US) | 47,954.99 | 104.05 | 0.22% |
| FTSE 100 | 9,667.01 | 43.86 | -0.45% |
| HKSE | 26,085.08 | 149.18 | 0.58% |
| NASDAQ | 23,578.13 | 72.99 | 0.31% |
| Nikkei 225 | 50,491.87 | 536.55 | -1.05% |
| NZX 50 Index | 13,483.99 | 31.63 | -0.23% |
| S&P 500 | 6,870.40 | 13.28 | 0.19% |
| S&P/ASX 200 | 8,634.60 | 20.50 | 0.24% |
| SSE Composite Index | 3,902.81 | 27.01 | 0.70% |